Cross Reference Logo
Citations to this article as recorded by CrossRef and RSC Journals (236 citations).

Nanomaterial-enabled metabolic reprogramming strategies for boosting antitumor immunity
Muye Ma, Yongliang Zhang, Kanyi Pu and Wei Tang
Chem. Soc. Rev., 2025, 54, 653
DOI: 10.1039/D4CS00679H

Radiation responsive PROTAC nanoparticles for tumor-specific proteolysis enhanced radiotherapy
Mengxia Xu, Yuyang Yun, Changjun Li, Yiling Ruan, Osamu Muraoka, Weijia Xie and Xiaolian Sun
J. Mater. Chem. B, 2024, 12, 3240
DOI: 10.1039/D3TB03046F

Chemically engineering cells for precision medicine
Yixin Wang, Zhaoting Li, Fanyi Mo, Ting-Jing Chen-Mayfield, Aryan Saini, Afton Martin LaMere and Quanyin Hu
Chem. Soc. Rev., 2023, 52, 1068
DOI: 10.1039/D2CS00142J

Rational design of the linkers in targeting chimeras
Yiping Duan, Michelle Y. Cai, Jinyi Xu and Quanyin Hu
Chem. Sci., 2025, 16, 17595
DOI: 10.1039/D5SC04859A

PROTAC approaches against drug-resistant EGFRC797S/L858R/T790M mutants: biological evaluation and SAR studies (2020–2025)
Ankush Kumar, Vishakha Sharma, Pallvi Kumari, Rajwinder Kaur and Rohit Bhatia
RSC Med. Chem., 2026
DOI: 10.1039/D5MD01113B

Chemistries of bifunctional PROTAC degraders
Chaoguo Cao, Ming He, Liguo Wang, Yuna He and Yu Rao
Chem. Soc. Rev., 2022, 51, 7066
DOI: 10.1039/D2CS00220E

Polymer-engineered PROTAC nanovehicles amplify synergistic effects with temozolomide by BRD4 degradation
Yun Guo, Haoyu You, Yiyang Li, Zheng Zhou, Zonghua Tian, Chen Jiang and Tao Sun
Biomater. Sci., 2025, 13, 5001
DOI: 10.1039/D5BM00443H

A platinated prodrug leveraging PROTAC technology for targeted protein degradation and enhanced antitumor efficacy
Jiaqian Xu, Shu Chen, Ka-Yan Ng, Xianfeng Chen, Wai Chung Fu and Guangyu Zhu
Inorg. Chem. Front., 2025, 12, 3981
DOI: 10.1039/D5QI00605H

Nano-PROTACs: state of the art and perspectives
Jie Zhong, Ruiqi Zhao, Yuji Wang, Yu-xiong Su and Xinmiao Lan
Nanoscale, 2024, 16, 4378
DOI: 10.1039/D3NR06059D

Proteolysis-targeting drug delivery system (ProDDS): integrating targeted protein degradation concepts into formulation design
Yu Chen, Fengyuan Liu, Samira Pal and Quanyin Hu
Chem. Soc. Rev., 2024, 53, 9582
DOI: 10.1039/D4CS00411F

Radioactive ADME Demonstrates ARV-110’s High Druggability Despite Low Oral Bioavailability
Yifei He, Yuandong Zheng, Chenggu Zhu, Peng Lei, Jinghua Yu, Chongzhuang Tang, Hao Chen and Xingxing Diao
J. Med. Chem., 2024, 67, 14277
DOI: 10.1021/acs.jmedchem.4c01104

Therapeutic potential of TRIM family proteins in gastric cancer: from signaling pathway regulation to precision targeting strategies
Caiqing Zhao, Jialing Qi, Zhenze Zhang, Qi Feng, Ziling Fang and Nian Fang
Front. Oncol., 2025, 15
DOI: 10.3389/fonc.2025.1628729

Targeted Protein Degradation: Methods and Prospects
Ilya V. Sklyar, Aleksandra M. Rozhkova, Elena G. Kondratyeva and Arkadiy P. Sinitsyn
Biochemistry Moscow, 2026, 91, S118
DOI: 10.1134/S0006297925604034

Recent Progress in DNA Damage Response-Targeting PROTAC Degraders
Binbin Cheng, Xiaoting Fei, Zongbao Ding, Xiaopeng Peng, Zhenhong Su, Wei Pan and Jianjun Chen
J. Med. Chem., 2024, 67, 6906
DOI: 10.1021/acs.jmedchem.4c00015

The Emergence of Oligonucleotide Building Blocks in the Multispecific Proximity-Inducing Drug Toolbox of Destruction
Kevin Xiao Tong Zhou and Katherine E. Bujold
ACS Chem. Biol., 2025, 20, 3
DOI: 10.1021/acschembio.4c00311

DYNLL1 ubiquitinated and degraded by E3 ligase PRKN regulates cell cycle arrest and apoptosis in lung adenocarcinoma cells
Hongjie Tang and Changjiang Wei
Discov Onc, 2024, 15
DOI: 10.1007/s12672-024-01686-7

A Dual-Targeted Molecule for Disease-Activatable Proteolysis Targeting Chimeras and Targeted Radionuclide Therapy of Cancer
Yuan Zhang, Wei Gu, Wan Chen, Jieli Zhu, Longfei Fan, Liwen Zhang, Liangyou Zhao and Qingqing Miao
J. Am. Chem. Soc., 2025, 147, 7897
DOI: 10.1021/jacs.4c18398

Phase 1 study of HP518, a PROTAC AR degrader in patients with mCRPC: results on safety, pharmacokinetics, and anti-tumor activity
Arun A. Azad, Howard Gurney, Craig Underhill, Lisa Horvath, Mark Voskoboynik, Xinghai Li, Ivan King, Lisa Shao, Yiyun Dai and Frank Perabo
Invest New Drugs, 2025, 43, 435
DOI: 10.1007/s10637-025-01533-8

The recent advance of Interleukin-1 receptor associated kinase 4 inhibitors for the treatment of inflammation and related diseases
Yi-Ru Bai, Wei-Guang Yang, Xue-Hui Hou, Dan-Dan Shen, Sheng-Nan Zhang, Yan Li, Yan-Yan Qiao, Sai-Qi Wang, Shuo Yuan and Hong-Min Liu
European Journal of Medicinal Chemistry, 2023, 258, 115606
DOI: 10.1016/j.ejmech.2023.115606

Sirtuin 3 as a promising target in disease therapy: Model action and drug discovery
Dongmin Yu
European Journal of Medicinal Chemistry, 2025, 297, 117929
DOI: 10.1016/j.ejmech.2025.117929

Unlocking precision medicine: Innovative strategies for druggable target identification and therapeutic enhancement
Yang Liao, Zhangle Wei, Hangwei Xu, Zhichao Zhang and Feng Zhu
Precision Medication, 2024, 1, 100002
DOI: 10.1016/j.prmedi.2024.10.002

Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy
Zhi-feng Zou, Lei Yang, Hui-jun Nie, Jing Gao, Shu-min Lei, Yi Lai, Fan Zhang, Ernst Wagner, Hai-jun Yu, Xiao-hua Chen and Zhi-ai Xu
Acta Pharmacol Sin, 2024, 45, 1740
DOI: 10.1038/s41401-024-01266-z

Discovery of Ligands for TRIM58, a Novel Tissue-Selective E3 Ligase
Klemens Hoegenauer, Shaojian An, Jake Axford, Christina Benander, Christian Bergsdorf, Josephine Botsch, Suzanne Chau, César Fernández, Scott Gleim, Ulrich Hassiepen, Juerg Hunziker, Emilie Joly, Aramis Keller, Sandra Lopez Romero, Robert Maher, Anne-Sophie Mangold, Craig Mickanin, Manuel Mihalic, Philippe Neuner, Andrew W. Patterson, Francesca Perruccio, Silvio Roggo, Julien Scesa, Martin Schröder, Dojna Shkoza, Binh Thai, Anna Vulpetti, Martin Renatus and John S. Reece-Hoyes
ACS Med. Chem. Lett., 2023, 14, 1631
DOI: 10.1021/acsmedchemlett.3c00259

Engineered platelets as targeted protein degraders and application to breast cancer models
Yu Chen, Samira Pal, Wen Li, Fengyuan Liu, Sichen Yuan and Quanyin Hu
Nat Biotechnol, 2025, 43, 1800
DOI: 10.1038/s41587-024-02494-8

Lysosome-targeted ROS-responsive graphene oxide-based drug delivery system to overcome tumor DOX resistance
Fengzhu Yang, Jintao Deng, Xinyu Yu, Wenhao Fu, Wenlong Sun, Zhengbao Xu, Xinhua Song, Chao Wang, Qingqing Du and Meng Wang
Colloids and Surfaces B: Biointerfaces, 2026, 261, 115434
DOI: 10.1016/j.colsurfb.2026.115434

Advancements in PROTAC-based therapies for neurodegenerative diseases
Deyuan Kong, Liying Meng, Pengfei Lin and Guanzhao Wu
Future Medicinal Chemistry, 2025, 17, 591
DOI: 10.1080/17568919.2025.2463310

An ultrasound-activated PROTAC prodrug with self-reporting fluorescence for targeted protein degradation
Tao Li, Yalan Tu, He Dong, Wenjiao Xie, Xiaoyu Pan and Youyong Yuan
Biomaterials, 2026, 330, 124045
DOI: 10.1016/j.biomaterials.2026.124045

Nanoliposomal Bcl-xL proteolysis-targeting chimera enhances anti-cancer effects on cervical and breast cancer without on-target toxicities
Jiaming Zhang, Baofang Zhang, Congli Pu, Jiarui Cui, Kexin Huang, Hongbo Wang and Yingchao Zhao
Adv Compos Hybrid Mater, 2023, 6
DOI: 10.1007/s42114-023-00649-w

The landscape of novel strategies for acute myeloid leukemia treatment: Therapeutic trends, challenges, and future directions
Ri Han Wu, Chen Ying Zhu, Pei Han Yu, Yafang Ma, Liaqat Hussain, Hua Naranmandura and Qian Qian Wang
Toxicology and Applied Pharmacology, 2023, 473, 116585
DOI: 10.1016/j.taap.2023.116585

Proteolytic platelets as targeted protein degraders

Nat Biotechnol, 2025, 43, 1770
DOI: 10.1038/s41587-024-02495-7

Chimeric peptide-engineered photodynamic PD-L1 degrader for activating colorectal cancer immunity in combination with exosomal PD-L1 inhibition
Yuxuan Wei, Zuxiao Chen, Wenfeng Zhu, Rongrong Zheng, Chuyu Huang, Ni Yang, Jing Wen, Dawei Zhang, Hong Cheng and Shiying Li
Sci. China Mater., 2025, 68, 2928
DOI: 10.1007/s40843-025-3431-y

Biomimetic Hybrid PROTAC Nanovesicles Block Multiple DNA Repair Pathways to Overcome Temozolomide Resistance Against Orthotopic Glioblastoma
Qing Xu, Xiangyu Hu, Ihsan Ullah, Taian Lin, Ye Liu, He Dong, Qingyu Zong, Youyong Yuan and Jun Wang
Advanced Materials, 2025, 37
DOI: 10.1002/adma.202504253

Biomacromolecule-mediated targeted protein degradation: an emerging strategy for cancer therapy
Meiyang Xi, Fengxia Zhang, Jingjing Zhu, Hualiang Shen, Chunlei Wu, Xiaozhong Gao, Huiting Xu, Yonghua Wu, Runpu Shen and Gang Xia
European Journal of Medicinal Chemistry, 2025, 298, 118019
DOI: 10.1016/j.ejmech.2025.118019

AI-powered omics-based drug pair discovery for pyroptosis therapy targeting triple-negative breast cancer
Boshu Ouyang, Caihua Shan, Shun Shen, Xinnan Dai, Qingwang Chen, Xiaomin Su, Yongbin Cao, Xifeng Qin, Ying He, Siyu Wang, Ruizhe Xu, Ruining Hu, Leming Shi, Tun Lu, Wuli Yang, Shaojun Peng, Jun Zhang, Jianxin Wang, Dongsheng Li and Zhiqing Pang
Nat Commun, 2024, 15
DOI: 10.1038/s41467-024-51980-9

Advances in Peptide-Based Chimeric Strategies for Targeted Protein Degradation
Yixuan Wang, Jingyuan Zhao, Hong Yuan and Shuai Li
J. Med. Chem., 2025, 68, 25708
DOI: 10.1021/acs.jmedchem.5c02379

Nanomedicine Targeting Myeloid‐Derived Suppressor Cells Enhances Anti‐Tumor Immunity
En‐Li Yang and Zhi‐Jun Sun
Adv Healthcare Materials, 2024, 13
DOI: 10.1002/adhm.202303294

PROTAC delivery in tumor immunotherapy: Where are we and where are we going?
Yiyang Li, Yike Wu, Sihan Gao, Tao Sun and Chen Jiang
Journal of Controlled Release, 2025, 378, 116
DOI: 10.1016/j.jconrel.2024.11.076

Supramolecular artificial Nano-AUTACs enable tumor-specific metabolism protein degradation for synergistic immunotherapy
Yazhen Wang, Lianyi Yang, Chenxing Yan, Yufan Du, Tinghua Li, Wenqing Yang, Lei Lei, Bin He, Huile Gao, Nicholas A. Peppas and Jun Cao
Sci. Adv., 2024, 10
DOI: 10.1126/sciadv.adn8079

Advancements and Challenges in Aptamer-Based Therapeutics and Diagnostics Across Diverse Medical Domains: A Comprehensive Review
Ahmed S.A. Ali Agha, Walhan Alshaer and Talal Aburjai
Jordan j. pharm. sci., 2024, 17, 344
DOI: 10.35516/jjps.v17i2.1895

Nano Proteolysis Targeting Chimeras (PROTACs) with Anti‐Hook Effect for Tumor Therapy
Ni‐Yuan Zhang, Da‐Yong Hou, Xing‐Jie Hu, Jian‐Xiao Liang, Man‐Di Wang, Zhang‐Zhi Song, Li Yi, Zhi‐Jia Wang, Hong‐Wei An, Wanhai Xu and Hao Wang
Angew Chem Int Ed, 2023, 62
DOI: 10.1002/anie.202308049

Recent advances in peptide-drug conjugates as anticancer agents
Yanyan Feng, Tong Li, Shijia Li, Zhouyan Liu, Ziwei Tang, Cheng Chen, Chen Zhou, Tulin Lu and Jichao Chen
European Journal of Medicinal Chemistry, 2026, 304, 118482
DOI: 10.1016/j.ejmech.2025.118482

Molecular features defining the efficiency of bioPROTACs
Dorothea Winkelvoß, David Vukovic, Anna-Carina Hänny, Luca Riermeier, Anto Udovcic, Jonas Kolibius, Annemarie Honegger, Peer R. E. Mittl, Erich Michel, Simon Hansen and Andreas Plückthun
Commun Biol, 2025, 8
DOI: 10.1038/s42003-025-08352-w

Development of visible-light-activatable photocaged PROTACs
Weizhi Weng, Gang Xue and Zhengying Pan
European Journal of Medicinal Chemistry, 2024, 265, 116062
DOI: 10.1016/j.ejmech.2023.116062

Precision-engineered PROTACs minimize off-tissue effects in cancer therapy
Jianghua Shi, Luo Wang, Xuanwei Zeng, Chengzhi Xie, Zhaowei Meng, Anahit Campbell, Lulu Wang, Heli Fan and Huabing Sun
Front. Mol. Biosci., 2024, 11
DOI: 10.3389/fmolb.2024.1505255

PROTACs as novel therapeutics against Mycobacterium tuberculosis: Current progress and future directions
Deepthi Ramesh and Ahammed Ameen Thottasseri
European Journal of Medicinal Chemistry, 2026, 308, 118718
DOI: 10.1016/j.ejmech.2026.118718

Nano-Proteolysis Targeting Chimeras (Nano-PROTACs) in Cancer Therapy
Yue Song, Qing-Qing Dong, Yi-Ke Ni, Xiao-Ling Xu, Chao-Xiang Chen and Wei Chen
IJN, 2024, Volume 19, 5739
DOI: 10.2147/IJN.S448684

Engineering Polymeric Nano-PROTAC for Targeted Protein Degradation and Cancer Therapy
Madiha Saeed, Zainab Amina, Zhiai Xu and Haijun Yu
Polymer Science & Technology, 2026
DOI: 10.1021/polymscitech.5c00122

Next‐Generation Proteolysis‐Targeting Chimeras in Precision Oncology: Multifunctional Designs, Emerging Modalities, and Translational Prospects in Targeted Protein Degradation
Mohamed S. Nafie, Mohamed K. Diab, Asmaa S. A. Yassen, Amany M. Elshamy, Mohamed R. El Tohamy, Haytham O. Tawfik and Sherif Ashraf Fahmy
Drug Development Research, 2025, 86
DOI: 10.1002/ddr.70192

Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
Gang Fan, Shilin Chen, Qingping Zhang, Na Yu, Ziyang Shen, Zhaoji Liu, Weiming Guo, Zhihan Tang, Jing Yang and Miao Liu
MedComm, 2025, 6
DOI: 10.1002/mco2.70401

HMGA2 promotes cancer metastasis by regulating epithelial–mesenchymal transition
Qing Ma, Sisi Ye, Hong Liu, Yu Zhao, Yan Mao and Wei Zhang
Front. Oncol., 2024, 14
DOI: 10.3389/fonc.2024.1320887

Challenges, opportunities, and therapeutic potential of JAK inhibitors and their derived PROTACs (2022 – 2023)
Rishi R Shah
Expert Opinion on Therapeutic Patents, 2025, 35, 571
DOI: 10.1080/13543776.2025.2477486

Application of Novel Degraders Employing Autophagy for Expediting Medicinal Research
Xiang Li, Qian Liu, Xin Xie, Cheng Peng, Qiwen Pang, Bo Liu and Bo Han
J. Med. Chem., 2023, 66, 1700
DOI: 10.1021/acs.jmedchem.2c01712

Acetyl-CoA Carboxylase Proteolysis-Targeting Chimeras: Conceptual Design and Application as Insecticides
Qi Xu, Hao Feng, Zhong Li and Xusheng Shao
J. Agric. Food Chem., 2024, 72, 18809
DOI: 10.1021/acs.jafc.4c02793

Coassembled Prodrug Nanoparticles Mitigating the Acquired Resistance to Protein Degradation Therapy
Jing Gao, Shumin Lei, Yiying Wang, Danni Sun, Lei Yang, Yi Lai, Junjing Zhang, Bruno D Geest, Liping Sun, Zhiai Xu and Haijun Yu
ACS Nano, 2026
DOI: 10.1021/acsnano.5c20138

Design and synthetic approaches to thalidomide based small molecule degraders
Ajeet Kumar, Gulshan Kumar, Nidhi Kalia and Priya Ranjan Sahoo
European Journal of Medicinal Chemistry, 2025, 293, 117700
DOI: 10.1016/j.ejmech.2025.117700

Co-assembling de novo designed peptide with high-payload drug protein for noninvasive treatment of corneal neovascularization
Yuhua Tong, Sijie Zhou, Yongjie Guo, Xiaoli Jin, Meiting Yu, Chunyun Feng, Hao Chen, Xingjie Zan and Jinyang Li
International Journal of Pharmaceutics: X, 2025, 10, 100410
DOI: 10.1016/j.ijpx.2025.100410

Liposomal formulation of the CDK9 PROTAC THAL-SNS-032 enhances the antitumor activity in breast cancer cell lines
María Arenas-Moreira, María del Mar Noblejas-López, Consuelo Ripoll, Carmen Moya-López, Cristina Díaz-Tejeiro, Alberto Ocaña, Luis Martin-Ezama, Iván Bravo and Carlos Alonso-Moreno
Biomedicine & Pharmacotherapy, 2025, 189, 118352
DOI: 10.1016/j.biopha.2025.118352

Non-invasive in vivo monitoring of PROTAC-mediated protein degradation using an environment-sensitive reporter
Tao Li, Qingyu Zong, He Dong, Ihsan Ullah, Zhenhai Pan and Youyong Yuan
Nat Commun, 2025, 16
DOI: 10.1038/s41467-025-57191-0

Multitargeted protein degradation: Integrating small-molecule, biomacromolecular, and nano-PROTACs for paradigm shifts in drug discovery
Jinghua Yang, Yujing Zhang, Miao Zhang, Dongming Xing and Chao Wang
Materials Today Advances, 2025, 28, 100644
DOI: 10.1016/j.mtadv.2025.100644

Conditional PROTAC: Recent Strategies for Modulating Targeted Protein Degradation
Junhyeong Yim, Junyoung Park, Gabin Kim, Hyung Ho Lee, Jin Soo Chung, Ala Jo, Minseob Koh and Jongmin Park
ChemMedChem, 2024, 19
DOI: 10.1002/cmdc.202400326

Discovery of 2,4-quinazolinedione derivatives as LC3B recruiters in the facilitation of protein complex degradations
Yanping Zeng, Jian Xiao, Li Shi, Yangsha Li, Yuanxin Xu, Jiayun Zhou, Xiao Dong, Haiyang Hou, Chao Zhong, Gang Cheng, Yi Chen, Naixia Zhang, Yanfen Fang and Youhong Hu
European Journal of Medicinal Chemistry, 2025, 287, 117293
DOI: 10.1016/j.ejmech.2025.117293

Targeted protein degradation in cancers: Orthodox PROTACs and beyond
Jin Li, Xinxin Chen, Aiping Lu and Chao Liang
The Innovation, 2023, 4, 100413
DOI: 10.1016/j.xinn.2023.100413

PARylation promotes acute kidney injury via RACK1 dimerization-mediated HIF-1α degradation
Xiangyu Li, Xiaoyu Shen, Xinfei Mao, Yuqing Wang, Yuhang Dong, Shuai Sun, Mengmeng Zhang, Jie Wei, Jianan Wang, Chao Li, Minglu Ji, Xiaowei Hu, Xinyu Chen, Juan Jin, Jiagen Wen, Yujie Liu, Mingfei Wu, Jutao Yu and Xiaoming Meng
Acta Pharmaceutica Sinica B, 2025, 15, 4673
DOI: 10.1016/j.apsb.2025.07.019

CRBN‐PROTACs in Cancer Therapy: From Mechanistic Insights to Clinical Applications
Riya Thapa, Asif Ahmad Bhat, Gaurav Gupta, S. Renuka Jyothi, Irwanjot Kaur, Sachin Kumar, Naveen Sharma, G. V. Siva Prasad, Atreyi Pramanik and Haider Ali
Chem Biol Drug Des, 2024, 104
DOI: 10.1111/cbdd.70009

The Peptide PROTAC Modality: A New Strategy for Drug Discovery
Youmin Zhu, Yu Dai and Yuncai Tian
MedComm, 2025, 6
DOI: 10.1002/mco2.70133

Self-Assembled Nano-PROTAC Enables Near-Infrared Photodynamic Proteolysis for Cancer Therapy
Weishan Wang, Chenghong Zhu, Bin Zhang, Yi Feng, Yan Zhang and Jinbo Li
J. Am. Chem. Soc., 2023, 145, 16642
DOI: 10.1021/jacs.3c04109

Targeting focal adhesion kinase (FAK) for cancer therapy: FAK inhibitors, FAK-based dual-target inhibitors and PROTAC degraders
Ming Yang, Hua Xiang and Guoshun Luo
Biochemical Pharmacology, 2024, 224, 116246
DOI: 10.1016/j.bcp.2024.116246

Injectable PROTAC-loaded hydrogel remodels the tumor microenvironment to potentiate radio-immunotherapy
Weihe Zhao, Xiangdong Xu, Shu An, Juehui Wu, Haiyang Wang, Jinmei Luo, Youyuan Yuan and Laisheng Li
Journal of Controlled Release, 2025, 387, 114200
DOI: 10.1016/j.jconrel.2025.114200

De Novo Design of Hexamer‐Linker Dual‐Action Nano‐PROTAC for Tumor‐Specific Ferroptosis
Ni‐Yuan Zhang, Zhuan Wen, Ming‐Ze Cai, Ke‐Ting Zhou, Hao‐Ze Li, Yi‐xuan Liu, Shang Wu, Yu Xia, Hong‐Wei An and Hao Wang
Angew Chem Int Ed, 2026, 65
DOI: 10.1002/anie.202509924

Current Status of Oligonucleotide-Based Protein Degraders
Po-Chang Shih, Miyako Naganuma, Yosuke Demizu and Mikihiko Naito
Pharmaceutics, 2023, 15, 765
DOI: 10.3390/pharmaceutics15030765

Split‐Deliver‐Click: Tumor‐Specific Protein Degradation via “AND” Logic‐Gated In‐Cell Bioorthogonal Clicking of PROTACs
He Dong, Cilong Chu, Ihsan Ullah, Qing Xu, Zhenhai Pan and Youyong Yuan
Angewandte Chemie, 2026, 138
DOI: 10.1002/ange.202520774

Recent breakthroughs in innovative elements, multidimensional enhancements, derived technologies, and novel applications of PROTACs
Si-Han Zhang, Na Zeng, Jin-Zhou Xu, Chen-Qian Liu, Meng-Yao Xu, Jian-Xuan Sun, Ye An, Xing-Yu Zhong, Lin-Tao Miao, Shao-Gang Wang and Qi-Dong Xia
Biomedicine & Pharmacotherapy, 2024, 180, 117584
DOI: 10.1016/j.biopha.2024.117584

PROTACs in Ovarian Cancer: Current Advancements and Future Perspectives
Makenzie Vorderbruggen, Carlos A. Velázquez-Martínez, Amarnath Natarajan and Adam R. Karpf
IJMS, 2024, 25, 5067
DOI: 10.3390/ijms25105067

PROTACs in Targeted Protein Degradation: Advances in Development and AI-Enhanced Drug Discovery
Mao Du, Tao Liu, Wenyu Wang, Shuai Fan, Mei Tian, Qing Du, Zhidong Wang, Xiaobo Li, Xiaoyu Liu, Qin Xia, Feng Wang and Lei Dong
European Journal of Medicinal Chemistry Reports, 2026, 100332
DOI: 10.1016/j.ejmcr.2026.100332

Prodrug Approach as a Strategy to Enhance Drug Permeability
Mateus Mello de Souza, Ana Luísa Rodriguez Gini, Jhonnathan Alves Moura, Cauê Benito Scarim, Chung Man Chin and Jean Leandro dos Santos
Pharmaceuticals, 2025, 18, 297
DOI: 10.3390/ph18030297

Unconventional PROTACs for Targeted Protein Degradation in Cancer Therapy
Xu Zhang, Zhangzhi Song, Xinyu Zhang, Jianhua Zou, Guocan Yu, Xiaoyuan Chen and Sheng Wang
Angewandte Chemie, 2025, 137
DOI: 10.1002/ange.202507702

A Novel Anti-PD-L1 Functionalized Protopanaxadiol-Liposome Loading Paclitaxel for Synergistic Immunochemical Therapy of Triple-Negative Breast Cancer
Yawen Yu, Ming-Yan Yang, Baifang Gong, Zhixia Wang, Ke Liu and Huaying Fan
Mol. Pharmaceutics, 2025, 22, 6728
DOI: 10.1021/acs.molpharmaceut.5c00701

Assembly/disassembly-based targeting protein degradation systems for cancer therapy
Hongzhe Yan, Xiaoyang Liu, Ying Xu, Gaolin Liang and Xiaofeng Wu
EngMedicine, 2026, 3, 100115
DOI: 10.1016/j.engmed.2025.100115

Characterization of preclinical radio ADME properties of ARV-471 for predicting human PK using PBPK modeling
Yifei He, Chenggu Zhu, Peng Lei, Chen Yang, Yifan Zhang, Yuandong Zheng and Xingxing Diao
Journal of Pharmaceutical Analysis, 2025, 15, 101175
DOI: 10.1016/j.jpha.2024.101175

Nucleic acid-encoded antibody gene transfer-next generation of antibody therapies
Kaikai Yu, Xiao Geng, Baichuan Chen, Na Xu and Wensen Liu
Drug Delivery, 2025, 32
DOI: 10.1080/10717544.2025.2566782

Folate‐PEG‐PROTAC Micelles for Enhancing Tumor‐Specific Targeting Proteolysis In Vivo
Junhui Ma, Lei Fang, Zhengjun Sun, Meijing Li, Ting Fan, Guangya Xiang and Xiang Ma
Adv Healthcare Materials, 2024, 13
DOI: 10.1002/adhm.202400109

An Overview of Liquid-Liquid Phase Separation and Its Mechanisms in Sepsis
Meiling Cao, Xinyi Zhang, Xiaohan Wang, Danyang Zhao, Mingyue Shi, Jiahui Zou, Lei Li and Hongkun Jiang
JIR, 2025, Volume 18, 3969
DOI: 10.2147/JIR.S513098

Targeted Protein Degradation Strategies for Lung Cancers: Focusing on Epidermal Growth Factor Receptor
Min Hou, Mingda Li, Jianghong Zhao, Yanfang Gong, Jing Rong, Zheng Feng, Huanhuan Sun and Jincheng Zeng
Chemistry & Biodiversity, 2026, 23
DOI: 10.1002/cbdv.202503126

Advancing Cancer Immunotherapy through Engineering New PD-L1 Degraders: A Comprehensive Study from Small Molecules to PD-L1-Specific Peptide–Drug Conjugates
Zekun Zeng, Zhiwei Yang, Chenghao Li, Shujing Liu, Wei Wei, Ye Zhou, Simeng Wang, Mengjun Sui, Mengdan Li, Shumei Lin, Yangyang Cheng and Peng Hou
J. Med. Chem., 2024, 67, 19216
DOI: 10.1021/acs.jmedchem.4c01652

De Novo Design of Hexamer‐Linker Dual‐Action Nano‐PROTAC for Tumor‐Specific Ferroptosis
Ni‐Yuan Zhang, Zhuan Wen, Ming‐Ze Cai, Ke‐Ting Zhou, Hao‐Ze Li, Yi‐xuan Liu, Shang Wu, Yu Xia, Hong‐Wei An and Hao Wang
Angewandte Chemie, 2026, 138
DOI: 10.1002/ange.202509924

Proteolysis-targeting Chimeras induce ferroptosis in cancer: From Mechanism to clinical application
Na Zeng, Xing-Yu Zhong, Si-Han Zhang, Mei-Cheng Liu, Qi-Dong Xia, Xiao Yu and Shao-Gang Wang
Pharmacological Research, 2026, 226, 108141
DOI: 10.1016/j.phrs.2026.108141

Advancements in Proteolysis Targeting Chimeras for Targeted Therapeutic Strategies in Alzheimer’s Disease
Qiuzhi Zhou, Weixia Wang and Chunchu Deng
Mol Neurobiol, 2025, 62, 9686
DOI: 10.1007/s12035-025-04838-0

Self-assembled Nano-PROTACs: bridging chemical design and biological barriers in targeted protein degradation
Ni-Yuan Zhang, Jian-Xiao Liang, Bei-Ning Hu, Yi Wang, Hong-Wei An and Hao Wang
Advanced Drug Delivery Reviews, 2026, 234, 115861
DOI: 10.1016/j.addr.2026.115861

Molecular mechanisms and potential targeting strategies of ubiquitin‑proteasome system‑mediated PD‑1/PD‑L1 ubiquitination in tumor immune suppression (Review)
Li-Hui Gu, Ai Guo, Yi-Yue Ding, Xue-Jie Wang, Hong-Xing Zhang, Wan-Li Duan and Bao-Gang Zhang
Oncol Rep, 2025, 54, 1
DOI: 10.3892/or.2025.9000

Development of Cathepsin B-Responsive GalNAc-PROTACs for Hepatocyte-Targeting Protein Degradation
Yunhua Peng, Tao Li, Donghua Liu, Wenxin Li, Yimeng Zhang, Ying Zhao, Xuehan Jiang, Yaqi Liang, Pengxiao Chen, Bohan Ma, Jing Liu and He Chen
J. Med. Chem., 2025
DOI: 10.1021/acs.jmedchem.5c02908

PROTAC for agriculture: learning from human medicine to generate new biotechnological weed control solutions
Ramon G. Leon and Diane C. Bassham
Pest Management Science, 2024, 80, 262
DOI: 10.1002/ps.7741

Discovery of a New and Selective HPK1 PROTAC for Enhancing Tumor Immunotherapy through Eliminating GLK Degradation
Mingfei Wu, Xinfei Mao, Yiquan Wu, Wentao Wang, Yuyuan Jin, Hengyuan Yu, Liuzhi Hu, Zheyuan Shen, Liteng Shen, Shenxin Zeng, Tengfei Xu, Yong Chen, Bo Zhang, Nengming Lin, Jinxin Che, Wenhai Huang and Xiaowu Dong
J. Med. Chem., 2025, 68, 10800
DOI: 10.1021/acs.jmedchem.4c02972

Stimuli-activatable protein degraders for targeted cancer therapy: from prodrug design to nanoplatform applications
Xingyu Jiang, Yinuo Chen, Yunna Gao, Rui Rong, Yi Lai, Zheying Zhu and Zhiai Xu
Advanced Drug Delivery Reviews, 2026, 232, 115808
DOI: 10.1016/j.addr.2026.115808

Synergizing CXCL9 with BRD4‐PROTAC Using Nanochaperone Boosts Robust T Cell‐Dependent Antitumor Immune Responses for Cancer Immunotherapy
Jiajing Chen, Feihe Ma, Yongxin Zhang, Mengchen Xu, Linlin Xu, Yang Liu, Rujiang Ma and Linqi Shi
Adv Funct Materials, 2024, 34
DOI: 10.1002/adfm.202314203

The rise of degrader drugs
Mingxing Teng and Nathanael S. Gray
Cell Chemical Biology, 2023, 30, 864
DOI: 10.1016/j.chembiol.2023.06.020

Proteolysis-targeting chimera (PROTAC) nanomedicines toward cancer treatment: From synthesis to therapeutic delivery
Yilin Liu, Xiao Zhang, Xiaoyuan Chen and Fuwu Zhang
Biomaterials, 2026, 325, 123621
DOI: 10.1016/j.biomaterials.2025.123621

What influences the activity of Degrader−Antibody conjugates (DACs)
Yaolin Guo, Xiaoxue Li, Yang Xie and Yuxi Wang
European Journal of Medicinal Chemistry, 2024, 268, 116216
DOI: 10.1016/j.ejmech.2024.116216

PROTAC delivery systems: Innovative approaches for cancer treatment
María Arenas-Moreira, Alberto Ocaña, Iván Bravo and Carlos Alonso-Moreno
Biomedicine & Pharmacotherapy, 2026, 194, 118892
DOI: 10.1016/j.biopha.2025.118892

Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications
Qiong Li, Li Zhou, Siyuan Qin, Zhao Huang, Bowen Li, Ruolan Liu, Mei Yang, Edouard C. Nice, Huili Zhu and Canhua Huang
European Journal of Medicinal Chemistry, 2023, 257, 115447
DOI: 10.1016/j.ejmech.2023.115447

Development of Novel PROTAC RAD51 Degraders as Enhancers of DNA Damage Response for Hepatocellular Carcinoma Treatment
Jinbo Huang, Haiyu Wang, Daohong Jiang, Longjiang Di, Jiayi Chen, Yuanqing Sun, Zhongyi Xie, Jun Zhang, Tingting Feng, Yerkezhan Yerkinkazhina, Yan Zhou, Jinqin Qian, Yuxin Shu and Wei-Guo Zhu
J. Med. Chem., 2026, 69, 3957
DOI: 10.1021/acs.jmedchem.5c02624

Tailoring albumin-based theranostic PROTACs nanoparticles for enhanced NIR-II bioimaging and synergistic cancer chemo-phototherapy
Zhuang Hu, Ruihan Li, Xinyue Cui, Changjun Hu and Zilin Chen
Chemical Engineering Journal, 2023, 469, 143883
DOI: 10.1016/j.cej.2023.143883

Design of Murine Double Minute 2 Proteolysis Targeting Chimera Degraders with a Built-In Tumor-Targeting Ability
Zhuqian Wang, Siran Yue, Xinxin Chen, Jin Li, Peixi Zhu, Hongzhen Chen, Fang Qiu, Duoli Xie, Yiying Liang, Defang Li, Aiping Lu and Chao Liang
J. Med. Chem., 2024, 67, 18865
DOI: 10.1021/acs.jmedchem.4c01228

(+)-JQ-1 alleviates cardiac injury in myocardial infarction by inhibiting ferroptosis through the NAMPT/SIRT1 pathway
Mengxue Yang, Ting Wang, Jingrong Shao, Xinna Ran, Rui Xiao, Rui Zhao, Chunyan Wu, Ming Ji, Weiping Tian, Huabing Sun, Jiao Liu and Shengkai Zuo
Cell Death Dis, 2025, 16
DOI: 10.1038/s41419-025-07880-x

Small-Molecule PROTACs for Cancer Immunotherapy
Zefan Liu, Yajun Zhang, Yucheng Xiang and Xin Kang
Molecules, 2022, 27, 5439
DOI: 10.3390/molecules27175439

Oxygen-Generating Transdermal Nanoplatform Codelivering BRD4 Proteolysis-Targeting Chimera/Verteporfin/CaO2 Synergistically Remodels Immunosuppressive Melanoma Microenvironment to Potentiate Combination Immunotherapy
Mingli Wei, Tian Yin, Chenxiao Chu, Muse Ji, Jiansong Zhao, Xinxin Liang, Xiaoshuang Bi, Jingxin Gou, Haibing He, Xing Tang and Yu Zhang
ACS Nano, 2025, 19, 25830
DOI: 10.1021/acsnano.5c04580

Unconventional PROTACs for Targeted Protein Degradation in Cancer Therapy
Xu Zhang, Zhangzhi Song, Xinyu Zhang, Jianhua Zou, Guocan Yu, Xiaoyuan Chen and Sheng Wang
Angew Chem Int Ed, 2025, 64
DOI: 10.1002/anie.202507702

Highly efficient and long-acting split-and-mix proteolysis targeting chimera based on self-assembled polylactic acid
Mei-miao Zhan, Hailing Chen, Meiling He, Chunli Song, Zijun Jiao, Na Liu, Zhihong Liu, Zhanfeng Hou, Ying Chen, Zhibo Song, Yun Xing, Zigang Li and Feng Yin
Nat Commun, 2025, 16
DOI: 10.1038/s41467-025-65590-6

Targeted protein degradation technologies: Emerging mechanisms and nano-based innovations
Mingge Hou, Runze Zhao, Shenghui Wang, Bing Jiang and Xiyun Yan
Nano Research, 2025, 18, 94907983
DOI: 10.26599/NR.2025.94907983

Nanobody-based bioPROTAC for viral protein degradation provides an antiviral strategy for porcine arterivirus
Shibo Su, Mingxia Sun, Haiwei Wang, Yan-Dong Tang, Jin Chen, Xinqi Shi, Shuang Cai, Hanrong Zhou, Wei Yang, Ning Zhang, Yongbo Yang, Shujie Wang, Kai Zhao, Hongliang Zhang, Zhijun Tian, Xuehui Cai, Yu Lu, Fandan Meng and Tongqing An
J Nanobiotechnol, 2026
DOI: 10.1186/s12951-026-04348-8

Integrating Proteolysis‐Targeting Chimeras (PROTACs) with Delivery Systems for More Efficient and Precise Targeted Protein Degradation
Jiachan Lin, Zirui Chen, Dan Zhang, Nan Zhang, Hongzhong Chen and Dong‐Sheng Guo
Macromol. Rapid Commun., 2025, 46
DOI: 10.1002/marc.202401051

Selective steroid receptor modulators, degraders and PROTACs: Therapeutic strategies in management of endocrine-related cancers
Anjali Tripathi, Ayushi Chhabra, Sheeba Rizvi and Rakesh K. Tyagi
Molecular and Cellular Endocrinology, 2025, 605, 112569
DOI: 10.1016/j.mce.2025.112569

Targeted Strategies for Degradation of Key Transmembrane Proteins in Cancer
Vehary Sakanyan, Nina Iradyan and Rodolphe Alves de Sousa
BioTech, 2023, 12, 57
DOI: 10.3390/biotech12030057

BRD4-targeted photodegradation nanoplatform for light activatable melanoma therapy
Shiman Lu, Zhaoqing Shi, Chendi Ding, Wenyan Wang, Weilang Zhang, Li Huang, Jiachan Lin, Xinpei Wang, Ran Luo, Xiaowei Zeng, Wenhu Zhou, Hongzhong Chen, Qiangsong Wang and Lin Mei
Biomaterials, 2025, 317, 123101
DOI: 10.1016/j.biomaterials.2025.123101

Synthesis, SAR, and application of JQ1 analogs as PROTACs for cancer therapy
Soumik De, Raghaba Sahu, Shubhendu Palei and Laxmi Narayan Nanda
Bioorganic & Medicinal Chemistry, 2024, 112, 117875
DOI: 10.1016/j.bmc.2024.117875

Investigating the cell permeability of proteolysis-targeting chimeras (PROTACs)
Hidetomo Yokoo, Mikihiko Naito and Yosuke Demizu
Expert Opinion on Drug Discovery, 2023, 18, 357
DOI: 10.1080/17460441.2023.2187047

Nanoenabled Strategies Enhancing PROTACs for Cancer Therapy
Rui Li, Shuhao Zhang, Yunxue Xu, Renfa Liu and Zhifei Dai
Bioconjugate Chem., 2025, 36, 1582
DOI: 10.1021/acs.bioconjchem.5c00305

Trends in Molecular Properties, Bioavailability, and Permeability across the Bayer Compound Collection
Daniel H. O’ Donovan, Claudia De Fusco, Lara Kuhnke and Andreas Reichel
J. Med. Chem., 2023, 66, 2347
DOI: 10.1021/acs.jmedchem.2c01577

PROTAC-biomacromolecule conjugates for precise protein degradation in cancer therapy: A review
Chao Wang, Yujing Zhang, Wanpeng Yu, Jiazhen Xu and Dongming Xing
International Journal of Biological Macromolecules, 2024, 261, 129864
DOI: 10.1016/j.ijbiomac.2024.129864

Programmable protein stabilization with language model-derived peptide guides
Lauren Hong, Tianzheng Ye, Tian Z. Wang, Divya Srijay, Howard Liu, Lin Zhao, Rio Watson, Sophia Vincoff, Tianlai Chen, Kseniia Kholina, Shrey Goel, Matthew P. DeLisa and Pranam Chatterjee
Nat Commun, 2025, 16
DOI: 10.1038/s41467-025-58872-6

CDT Prodrug Therapy With Cascade‐Activated PROTAC Delivery Platform for Mutually Reinforced Ferroptosis and Apoptosis‐Based Therapy
Minxia Xu, Yiling Ruan, Jinglang Gong, Mengxia Xu, Jingjing Shen, Lin Wang and Xiaolian Sun
Adv Funct Materials, 2026, 36
DOI: 10.1002/adfm.202521641

Epigenetic therapy meets targeted protein degradation: HDAC-PROTACs in cancer treatment
Md Sadique Hussain, Liming Zhang, Amita Joshi Rana, Mudasir Maqbool, Sumel Ashique, Yumna Khan, Vikas Jakhmola, Ali Hanbashi, Wedad Mawkili and Gyas Khan
Future Medicinal Chemistry, 2025, 17, 1725
DOI: 10.1080/17568919.2025.2533113

Proteolysis Targeting Chimeras (PROTACs) based on celastrol induce multiple protein degradation for triple-negative breast cancer treatment
Xuelan Gan, Fan Wang, Jianguo Luo, Yunfei Zhao, Yan Wang, Chao Yu and Jun Chen
European Journal of Pharmaceutical Sciences, 2024, 192, 106624
DOI: 10.1016/j.ejps.2023.106624

Preparation and Characterization of Ternary Complexes to Improve the Solubility and Dissolution Performance of a Proteolysis-Targeting Chimera Drug
Heng Zhang, Hengqian Wu, Lili Wang, Laura Machín Galarza, Chuanyu Wu, Mingzhong Li, Zhengping Wang, Erpeng Zhou and Jun Han
Pharmaceutics, 2025, 17, 671
DOI: 10.3390/pharmaceutics17050671

Proteolysis-targeting chimera-doxorubicin conjugate nanoassemblies for dual treatment of EGFR-TKI sensitive and resistant non-small cell lung cancer
Junhui Ma, Ruixue Zhu, Meijing Li, Hui Jiao, Sijun Fan, Xiang Ma and Guangya Xiang
Acta Biomaterialia, 2025, 195, 421
DOI: 10.1016/j.actbio.2025.02.012

Self-Assembled Peptide PROTAC Prodrugs Targeting FOXM1 for Cancer Therapy
Huajie Zeng, Zhiguo Fang, Yinghua Feng, Tong Su, Weibing Miao and Zihua Wang
Mol. Pharmaceutics, 2025, 22, 3286
DOI: 10.1021/acs.molpharmaceut.5c00219

Small Molecule–Degrader Conjugates: Evaluating the Structure–Activity Relationship of Linkers to Overcome In Vivo Barriers in PROTAC Delivery
Shiwei Song, Weina Jing, Lei Peng, Jiaqi Liu and Wanyi Tai
J. Med. Chem., 2025, 68, 17323
DOI: 10.1021/acs.jmedchem.5c00862

Welding PROxAb Shuttles: A Modular Approach for Generating Bispecific Antibodies via Site-Specific Protein–Protein Conjugation
Tanja Lehmann, Hendrik Schneider, Jason Tonillo, Jennifer Schanz, Daniel Schwarz, Christian Schröter, Sebastian Jäger, Harald Kolmar, Stefan Hecht, Jan Anderl, Nicolas Rasche, Marcel Rieker and Stephan Dickgiesser
Bioconjugate Chem., 2024, 35, 780
DOI: 10.1021/acs.bioconjchem.4c00124

TRL-PROTAC: A pre-trained generator of PROTACs targeting specific proteins optimized by reinforcement learning
Yuhao Dai and Fei Zhu
ComSIS, 2024, 21, 1293
DOI: 10.2298/CSIS240327039D

The Human Intermediate Prolactin Receptor I-tail Contributes Breast Oncogenesis by Targeting Ras/MAPK Pathway
Shanwei Shen, Senthil K Radhakrishnan, J Chuck Harrell, Madhavi Puchalapalli, Jennifer Koblinski and Charles Clevenger
Endocrinology, 2024, 165
DOI: 10.1210/endocr/bqae039

Recent Studies and Progress in the Intratumoral Administration of Nano-Sized Drug Delivery Systems
Wan Su Yun, Jeongrae Kim, Dong-Kwon Lim, Dong-Hwee Kim, Seong Ik Jeon and Kwangmeyung Kim
Nanomaterials, 2023, 13, 2225
DOI: 10.3390/nano13152225

Discovery of novel PDE4 degraders with in vivo anti-inflammatory efficacy
Yuanhui Liu, Hongliang Yao, Yanghui Ou, Lishan Hu, Wei Pan, Mengjie Li, Yali Zhang, Jun Wang, Jiaxin Chen, Xudong Qian, Jiayu Li, Peiming Huang, Gong Chen, Gang Li and Lianbao Ye
Bioorganic Chemistry, 2025, 163, 108675
DOI: 10.1016/j.bioorg.2025.108675

Radiotherapy-Triggered Proteolysis Targeting Chimera Prodrug Activation in Tumors
Chunrong Yang, Yuchen Yang, Yujie Li, Qiankun Ni and Jinghong Li
J. Am. Chem. Soc., 2023, 145, 385
DOI: 10.1021/jacs.2c10177

CNS delivery of targeted protein degraders
Prashant Agarwal, Darren L. Reid and Mansoor Amiji
Journal of Controlled Release, 2024, 372, 661
DOI: 10.1016/j.jconrel.2024.06.057

Peptide-Based PROTACs: Transitioning from Static Paradigm to a Dynamic Landscape within Targeted Protein Degradation
Xinchen Lu and Quanyin Hu
Bioconjugate Chem., 2026
DOI: 10.1021/acs.bioconjchem.6c00029

Applications of smart responsive nanomaterials in the theranostics of gastrointestinal malignancies: Current status and future perspectives
Wenpeng Huang, Jingwei Zhou, Yutong Liang, Rachel J. Saladin, Liming Li, Lei Kang, Chen Hua and Weibo Cai
Coordination Chemistry Reviews, 2025, 535, 216641
DOI: 10.1016/j.ccr.2025.216641

Advances in novel modification strategies for enhancing the tumor tissue specificity of PROTACs
Liuzhi Hu, Shuang Wu, Wentao Wang, Hongbo He, Jinxin Che, Mingfei Wu and Xiaowu Dong
European Journal of Medicinal Chemistry, 2026, 305, 118499
DOI: 10.1016/j.ejmech.2025.118499

DCAF13 inhibits the p53 signaling pathway by promoting p53 ubiquitination modification in lung adenocarcinoma
Shan Wei, Jing Xing, Jia Chen, Liping Chen, Jiapei Lv, Xiaofei Chen, Tang Li, Tao Yu, Huaying Wang, Kai Wang and Wanjun Yu
J Exp Clin Cancer Res, 2024, 43
DOI: 10.1186/s13046-023-02936-2

Co-delivery of PROTAC and siRNA via novel liposomes for the treatment of malignant tumors
Wenkai Zhang, Yi Jin, Jiayu Wang, Muge Gu, Yue Wang, Xiangqi Zhang, Yihui Zhang, Wei Yu, Yao Liu, Wei-En Yuan and Jing Su
Journal of Colloid and Interface Science, 2025, 678, 896
DOI: 10.1016/j.jcis.2024.08.185

Advancing Proteolysis Targeting Chimera (PROTAC) Nanotechnology in Protein Homeostasis Reprograming for Disease Treatment
Mengyao Wu, Yilan Zhao, Chi Zhang and Kanyi Pu
ACS Nano, 2024, 18, 28502
DOI: 10.1021/acsnano.4c09800

Sequential responsive nano-PROTACs for precise intracellular delivery and enhanced degradation efficacy in colorectal cancer therapy
Liuqing Yang, Ye Yang, Jing Zhang, Minghui Li, Long Yang, Xing Wang, Meifang Chen, Hua Zhang, Bing He, Xueqing Wang, Wenbing Dai, Yiguang Wang and Qiang Zhang
Sig Transduct Target Ther, 2024, 9
DOI: 10.1038/s41392-024-01983-1

PROTACs as Therapeutic Modalities for Drug Discovery in Castration-Resistant Prostate Cancer
Ling-Yu Wang, Chiu-Lien Hung, Tsan-Chun Wang, Hung-Chih Hsu, Hsing-Jien Kung and Kwang-Huei Lin
Annual Review of Pharmacology and Toxicology, 2025, 65, 375
DOI: 10.1146/annurev-pharmtox-030624-110238

Delivering on Cell‐Selective Protein Degradation Using Chemically Tailored PROTACs
Rui Yao, Tianli Luo and Ming Wang
ChemBioChem, 2023, 24
DOI: 10.1002/cbic.202300413

Programmable DNA Nanospheres for Photothermal‐Controlled Intracellular Protein Degradation
Yu Chen, Zongkang Guo, Hang Xiao, Wei Cai, Ziyue Peng, Kemin Wang, Wende Xiao and Jin Huang
Angewandte Chemie, 2026, 138
DOI: 10.1002/ange.202517452

Autophagy-Activating Nanoautophagosome-Tethering Compounds for Targeted Protein Degradation Specifically in Tumor Cells
Mengchen Xu, Jiajing Chen, Shuyu Wang, Linlin Xu, Xiaohui Wu, Jinpu Yu, Feihe Ma and Linqi Shi
ACS Macro Lett., 2025, 14, 250
DOI: 10.1021/acsmacrolett.4c00789

Recent advances in dual PROTACs degrader strategies for disease treatment
Jianyu Liu, Yanzhuo Liu, Jiao Tang, Qianyuan Gong, Guoyi Yan, Hengrui Fan, Xueping Zhang and Chunlan Pu
European Journal of Medicinal Chemistry, 2024, 279, 116901
DOI: 10.1016/j.ejmech.2024.116901

Developments of PROTACs technology in immune-related diseases
Chao Wang, Yujing Zhang, Junwen Deng, Bing Liang and Dongming Xing
European Journal of Medicinal Chemistry, 2023, 249, 115127
DOI: 10.1016/j.ejmech.2023.115127

Nano Proteolysis Targeting Chimeras (PROTACs) with Anti‐Hook Effect for Tumor Therapy
Ni‐Yuan Zhang, Da‐Yong Hou, Xing‐Jie Hu, Jian‐Xiao Liang, Man‐Di Wang, Zhang‐Zhi Song, Li Yi, Zhi‐Jia Wang, Hong‐Wei An, Wanhai Xu and Hao Wang
Angewandte Chemie, 2023, 135
DOI: 10.1002/ange.202308049

Liposomes-mediated enhanced antitumor effect of docetaxel with BRD4-PROTAC as synergist for breast cancer chemotherapy/immunotherapy
Xixi Chen, Fang Li, Binghui Cui, Qingyi Yan, Caisheng Qiu, Zengyan Zhu, Lijuan Wen and Weiliang Chen
International Journal of Pharmaceutics, 2025, 668, 124973
DOI: 10.1016/j.ijpharm.2024.124973

New insights into protein–protein interaction modulators in drug discovery and therapeutic advance
Hossam Nada, Yongseok Choi, Sungdo Kim, Kwon Su Jeong, Nicholas A. Meanwell and Kyeong Lee
Sig Transduct Target Ther, 2024, 9
DOI: 10.1038/s41392-024-02036-3

Nanotechnology Advances Proteolysis Targeting Chimeras (PROTACs): Transition From Basic Research to Clinical Application
Xupeng Mu, Chongqiang Mu, Mengxue Wang, Chen Meng, Huimin Liu and Haibin Lu
IJN, 2025, Volume 20, 12177
DOI: 10.2147/IJN.S552644

Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer
Qiao-Hong Chen, Erick Munoz and Dennis Ashong
Cancers, 2024, 16, 663
DOI: 10.3390/cancers16030663

MOF-based nanoparticles for tumor-targeted protein degradation and photodynamic therapy induce enhanced anti-tumor immunity
Huanhuan Zhu, Fei Gao, Yuan Li, Min Jiang, Yue Zhang, Chen Kan, Lin Han, Shaobo Xue, Kesheng Wang, Qiangyuan Fan, Honggang Hu, Fenyong Sun and Zunzhen Ming
Nano Today, 2024, 56, 102308
DOI: 10.1016/j.nantod.2024.102308

Utilizing aptamers in targeted protein degradation strategies for disease therapy
Lin Li, Songbo Xie, Jun Zhou and Jie Ran
The Journal of Pathology, 2025, 266, 134
DOI: 10.1002/path.6422

Advancing cancer immunotherapy: Small-Molecule, biomacromolecular, and nanoscale PROTACs targeting PD-L1 for degradation
Yang Meng, Yujing Zhang, Wanpeng Yu, Dongming Xing and Chao Wang
Materials Today Advances, 2025, 27, 100606
DOI: 10.1016/j.mtadv.2025.100606

Research progress in DNA damage response (DDR)-targeting modulators: From hits to clinical candidates
Binbin Cheng, Zongbao Ding, Yimeng Hong, Yaping Wang, Yingxing Zhou, Jianjun Chen, Xiaopeng Peng and Chunlai Zeng
European Journal of Medicinal Chemistry, 2025, 287, 117347
DOI: 10.1016/j.ejmech.2025.117347

Modeling of FAK-PROTAC candidates from GSK2256098 analogs for targeted protein degradation
Vikas Kumar, Shraddha Parate, Hyeon-Su Ro, Tae Sung Jung and Keun Woo Lee
Biochemical and Biophysical Research Communications, 2024, 740, 151001
DOI: 10.1016/j.bbrc.2024.151001

Functionalized Photoimmune Hydrogel Microspheres for Inside‐Out Eradication of Osteosarcoma via a PD‐L1 PROTAC Strategy
Huanhuan Luo, Jun Ma, Haiyang Yang, Haodong Hu, Zhuoming Xu, Lingli Jin, Jiayi Chen, Chenhong Qian, Jingyi Ju, Yongqing Zhang, Li Zheng, Kang Ji, Yi Li and Gang Chen
Adv Healthcare Materials, 2026, 15
DOI: 10.1002/adhm.202503988

Dual‐Programmable Semiconducting Polymer NanoPROTACs for Deep‐Tissue Sonodynamic‐Ferroptosis Activatable Immunotherapy
Fengshuo Wang, Guoqiang Dong, Mengbin Ding, Ningyue Yu, Chunquan Sheng and Jingchao Li
Small, 2024, 20
DOI: 10.1002/smll.202306378

Near-Infrared-Activatable PROTAC Nanocages for Controllable Target Protein Degradation and On-Demand Antitumor Therapy
Qi He, Liming Zhou, Daxin Yu, Ren Zhu, Yue Chen, Mingbo Song, Xintong Liu, Yixian Liao, Tong Ding, Wenpei Fan and Wenying Yu
J. Med. Chem., 2023, 66, 10458
DOI: 10.1021/acs.jmedchem.3c00587

PROTAC Delivery Strategies for Overcoming Physicochemical Properties and Physiological Barriers in Targeted Protein Degradation
Endry Wahyu Syahputra, Hyunji Lee, Hyukjun Cho, Hyun Jin Park, Kwang-Su Park and Duhyeong Hwang
Pharmaceutics, 2025, 17, 501
DOI: 10.3390/pharmaceutics17040501

Aptamer-Based Targeted Protein Degradation
Yuan Liu, Xu Qian, Chunyan Ran, Longjie Li, Ting Fu, Dan Su, Sitao Xie and Weihong Tan
ACS Nano, 2023, 17, 6150
DOI: 10.1021/acsnano.2c10379

Current advances of small molecule E3 ligands for proteolysis-targeting chimeras design
Dazhao Mi, Yuzhan Li, Haijun Gu, Yan Li and Yihua Chen
European Journal of Medicinal Chemistry, 2023, 256, 115444
DOI: 10.1016/j.ejmech.2023.115444

Sono‐Responsive Hydrogel for Fractionated PROTAC Release to Alleviate Resistance and Immunosuppression Induced by Multi‐Course Postoperative Radiotherapy
Haiyang Wang, Yixuan Hou, Taian Lin, Ihsan Ullah, Qing Xu, Ye Liu, Taosha Jin, Yangning Zhang and Youyong Yuan
Adv Funct Materials, 2026, 36
DOI: 10.1002/adfm.202512954

Targeting BRD4 in cancer therapy: From inhibitors and degraders to novel combination strategies and resistance mechanisms
Xi-Bo Wang, Rui-Jing Meng, Wen-Jin Cao, Lei Cheng, Junmin Zhang and Shi-Wu Chen
Bioorganic & Medicinal Chemistry, 2026, 132, 118473
DOI: 10.1016/j.bmc.2025.118473

Versatile Split-and-Mix Liposome PROTAC Platform for Efficient Degradation of Target Protein In Vivo
Chunli Song, Zijun Jiao, Zhanfeng Hou, Yun Xing, Xinrui Sha, Yuechen Wang, Jiaxin Chen, Susheng Liu, Zigang Li and Feng Yin
JACS Au, 2024, 4, 2915
DOI: 10.1021/jacsau.4c00278

Multifunctional Engineered Metal–Organic Frameworks as Targeted Protein Degraders for Augmenting Cancer Therapy via Hexokinase 2 Degradation and Provoking Cuproptosis
Shasha Li, Runjie Liu, Qixuan Zhang, Jiahui Sun, Hao Hao, Chenhao Yao, Li Yan, Dan Yang and Dechun Liu
Research, 2026, 9
DOI: 10.34133/research.1217

Advancements in delivery Systems for Proteolysis-Targeting Chimeras (PROTACs): Overcoming challenges and expanding biomedical applications
Yawei Yu, Weitong Hu, Yihua Xu, Hong-bin Xu and Jianqing Gao
Journal of Controlled Release, 2025, 382, 113719
DOI: 10.1016/j.jconrel.2025.113719

Evolution of proteolysis-targeting chimeras (PROTAC) technology to overcome challenges of antimicrobial resistance
Dhanashree N. Sarwan, Pramod B. Khedekar, Ritesh P. Bhole and Rupesh V. Chikhale
npj Antimicrob Resist, 2025, 3
DOI: 10.1038/s44259-025-00136-w

Ginsenoside Rh2- functionalized liposomes enhanced BRD4-PROTAC delivery and antitumor efficacy via improved tumor targeting and ECM remodeling
Lijuan Wen, Jialei Rao, Jiaoting Chen, Fang Li, Xixi Chen, Shenpeng Guo, Binghui Cui, Caisheng Qiu and Weiliang Chen
Materials Today Bio, 2026, 36, 102767
DOI: 10.1016/j.mtbio.2026.102767

Characteristic roadmap of linker governs the rational design of PROTACs
Yawen Dong, Tingting Ma, Ting Xu, Zhangyan Feng, Yonggui Li, Lingling Song, Xiaojun Yao, Charles R. Ashby and Ge-Fei Hao
Acta Pharmaceutica Sinica B, 2024, 14, 4266
DOI: 10.1016/j.apsb.2024.04.007

NanoTAC in targeted protein degradation: Intelligent delivery platforms and synergistic therapeutic paradigms
Jieying Qian, Hongtao Duan, Qingqi Zheng, Yuzhao Yang, Xiaowan Huang, Bingyang Shi and Yunjiao Zhang
Advanced Drug Delivery Reviews, 2026, 232, 115821
DOI: 10.1016/j.addr.2026.115821

Charge-reversal proteolysis polymers enable tissue-specific STING degradation in rheumatoid arthritis
Xu He, Lidong Gong, Juqi Zhang, Xiaocong Pang, Yuhui Li, Wei Wei, Yimin Cui and Zhiqiang Lin
Proc. Natl. Acad. Sci. U.S.A., 2026, 123
DOI: 10.1073/pnas.2525897123

Small-Molecule Ferritin Degrader as a Pyroptosis Inducer
Yu Chen, Wen Li, Song Kwon, Yixin Wang, Zhaoting Li and Quanyin Hu
J. Am. Chem. Soc., 2023, 145, 9815
DOI: 10.1021/jacs.3c01852

Dysregulation of ubiquitination modification in renal cell carcinoma
Hongjie You, Hui Zhang, Xiaofeng Jin and Zejun Yan
Front. Genet., 2024, 15
DOI: 10.3389/fgene.2024.1453191

Ionizable Nano‐PROTAC Overcomes Endosomal Entrapment for Enhanced LRG1 Degradation and Tumor Suppression
Huan Min, Ming Chao Sun, Kaijing Hu, Yana Zhang, Junyao Li, Yongzheng Li, Lin Du, Wei Ding, Yinlong Zhang, Guangjun Nie and Yingqiu Qi
Angewandte Chemie, 2026, 138
DOI: 10.1002/ange.202520235

JAK1/JAK2 degraders based on PROTAC for topical treatment of atopic dermatitis
Junchao Wu, Lisha Li, Quangang Zhu, Tingrui Zhang, Fengze Miao, Zhen Cui, Guoqiang Dong, Zongguang Tai and Zhongjian Chen
Biomedicine & Pharmacotherapy, 2024, 171, 116167
DOI: 10.1016/j.biopha.2024.116167

Tumor microenvironment responsive nano-PROTAC for BRD4 degradation enhanced cancer photo-immunotherapy
Zheng Li, Guodong Ren, Xuewei Wang, Xiaowan Li, Lingwen Ding, Jianwei Zhu, Yajie Zhang, Chengwu Zhang, Jianhua Zou and Xiaoyuan Chen
Biomaterials, 2025, 322, 123387
DOI: 10.1016/j.biomaterials.2025.123387

Boosting bioavailability of PROTACs for ovarian cancer: From chemistry to clinical translation
Mokhtar Rejili, Md Sadique Hussain, Faouzi Haouala, Yumna Khan, Mudasir Maqbool and Gaurav Gupta
Bioorganic Chemistry, 2025, 166, 109097
DOI: 10.1016/j.bioorg.2025.109097

Degraders on Demand: Engineering Smart Nanocarriers for PROTAC Delivery
Antalin Casmie Amalraj and Vijaya Parthasarathy
Mol. Pharmaceutics, 2026, 23, 622
DOI: 10.1021/acs.molpharmaceut.5c01070

Endogenous tyrosinase-catalyzed therapeutics
Yawen You, Zhaochen Guo, Yixin Wang, Sichen Yuan and Quanyin Hu
Nat Commun, 2025, 16
DOI: 10.1038/s41467-025-61799-7

Dual-targeting fluorous peptide proteolysis-targeting chimeras for cancer therapy
Guangyu Rong, Yuhan Li, Fang Zhu, Yiteng Lu, Zhengwang Sun, Jiaxu Hong and Yiyun Cheng
Journal of Controlled Release, 2026, 391, 114591
DOI: 10.1016/j.jconrel.2025.114591

Development and Evaluation of Liposomal Celastrol-PROTACs for Treating Triple-Negative Breast Cancer
Xuebin Li, Chaoqun Yu, Gongyi Zheng, Yanghong Li, Weiguo Cao and Fan Wang
Pharmaceuticals, 2025, 18, 1381
DOI: 10.3390/ph18091381

Dynamic Detection of the E3-PROTAC-Target Protein Ternary Complex In Vitro and In Vivo via Bimolecular Fluorescence Complementation
Kunjian Lei, Yilei Sheng, Yishuang Li, Zhihong Zhou, Xingen Zhu and Kai Huang
ACS Omega, 2024, 9, 49739
DOI: 10.1021/acsomega.4c08186

PROTACs in action: a novel strategy for pancreatic cancer
Rohit Sharma, Rahul Sharma, Sourabh Kumar, Rashmi Ghosh, Kumari Komal and Manish Kumar
Expert Review of Anticancer Therapy, 2025, 25, 1121
DOI: 10.1080/14737140.2025.2531235

New-generation advanced Nano-PROTACs as potential therapeutic agents in cancer therapy
Jingjuan Zhang, Yongzheng Li, Huiyuan Jin, Peizhen Yang, Huan Min, Jian Song and Yingqiu Qi
Journal of Controlled Release, 2026, 392, 114673
DOI: 10.1016/j.jconrel.2026.114673

Advances in light-activated PROTACs and phototherapy-combined approaches for cancer treatment
Wei Zhang, Shuai Li, Hong Yuan and Jingyuan Zhao
European Journal of Medicinal Chemistry, 2026, 302, 118310
DOI: 10.1016/j.ejmech.2025.118310

New PROTAC Designs for Targeted Protein Degradation in 2021–2025: Novel E3 Ligases and Pre-PROTACs
Wei Peng, Xiaoyan Pan, Shiqun Wang, Guang Huang and Yufeng Qian
J. Med. Chem., 2026
DOI: 10.1021/acs.jmedchem.5c03330

Tuna Collagen-Based hydrogels for the targeted delivery of BET inhibitors and BET-PROTACs in breast cancer therapy
Irene Sevilla-Carrillo, Carolina Hermida-Merino, Inmaculada Posadas, Martin Kreuzer, María del Mar Noblejas-López, Alberto Ocaña, Jesús Valcárcel, Daniel Hermida-Merino, Manuel M. Piñeiro, Carlos Alonso-Moreno and Iván Bravo
European Journal of Pharmaceutics and Biopharmaceutics, 2025, 217, 114898
DOI: 10.1016/j.ejpb.2025.114898

Discovery of Novel Proteolysis-Targeting Chimera Molecules as Degraders of Programmed Cell Death-Ligand 1 for Breast Cancer Therapy
Hongjia Zhang, Yan Zhang, Zhanzhan Feng, Ming Shuai, Xinyu Ma, Shirui Wang, Su Yu, Rui Deng, Dan Luo, Jianyou Shi, Chunlan Pu and Rui Li
J. Med. Chem., 2024, 67, 10589
DOI: 10.1021/acs.jmedchem.3c02259

PROTACs: Current and Future Potential as a Precision Medicine Strategy to Combat Cancer
Kailee A. Rutherford and Kirk J. McManus
Molecular Cancer Therapeutics, 2024, 23, 454
DOI: 10.1158/1535-7163.MCT-23-0747

Antitumour vaccination via the targeted proteolysis of antigens isolated from tumour lysates
Yu Zhao, Donghui Song, Zeyu Wang, Qingqing Huang, Fan Huang, Zhongfeng Ye, Douglas Wich, Mengting Chen, Jennifer Khirallah, Shuliang Gao, Yang Liu and Qiaobing Xu
Nat. Biomed. Eng, 2024, 9, 234
DOI: 10.1038/s41551-024-01285-5

New-generation advanced PROTACs as potential therapeutic agents in cancer therapy
Chao Wang, Yujing Zhang, Wujun Chen, Yudong Wu and Dongming Xing
Mol Cancer, 2024, 23
DOI: 10.1186/s12943-024-02024-9

Hydrogels for Cancer Immunotherapy: Strategies From Construction to Application
Xiaohua Chen, Shan Wu, Yueyang Zhang, Lilu Feng, Yang Chen, Xuzhao Yang, Ke Men, Jiuqun Zhu and Ming Li
MedComm, 2026, 7
DOI: 10.1002/mco2.70615

The role and mechanism of post-translational modifications (PTMs) in immune-related eye diseases
Yakun Wang, Xianyang Liu, Shuhao Zeng, Wenxian Yang, Fan Cao and Shengping Hou
Experimental Eye Research, 2026, 264, 110851
DOI: 10.1016/j.exer.2026.110851

Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy
Yujeong Moon, Seong Ik Jeon, Man Kyu Shim and Kwangmeyung Kim
Pharmaceutics, 2023, 15, 411
DOI: 10.3390/pharmaceutics15020411

PROTAC‑Mediated HMGCR Depletion Reprograms Lipid Metabolism in Breast Cancer to Potentiate Photoimmunotherapy via Ferroptosis
Tong Su, Guang Li, Yudong Guan, Qi Tian, Youzhi Qi, Yanqiu Zhang, Wenqian Wei, Xinxin Duan, Jiaxin Rui, Hongyan Zhu, Zengping Lin, Changchuan Xie, Zheni Xu, Yaying Wu, Xin Peng, Zhenjie Wang, Kun Chen, Xiaoyan Xin and Bing Zhang
Advanced Science, 2026, 13
DOI: 10.1002/advs.202521525

Self‐Oxygenating PROTAC Microneedle for Spatiotemporally‐Confined Protein Degradation and Enhanced Glioblastoma Therapy
Xingyu Jiang, Yi Lai, Wenzheng Xia, Wenfang Yang, Junjue Wang, Jiaxing Pan, Qian Zhao, Feng Zhou, Shiqin Li, Shunan Zhang, Jing Gao, Yinyan Wang, Tao Zan, Zhi Ping Xu, Haijun Yu and Zhiai Xu
Advanced Materials, 2025, 37
DOI: 10.1002/adma.202411869

Cell-based relay delivery strategy in biomedical applications
Yu Chen, Samira Pal and Quanyin Hu
Advanced Drug Delivery Reviews, 2023, 198, 114871
DOI: 10.1016/j.addr.2023.114871

Programmable DNA Nanospheres for Photothermal‐Controlled Intracellular Protein Degradation
Yu Chen, Zongkang Guo, Hang Xiao, Wei Cai, Ziyue Peng, Kemin Wang, Wende Xiao and Jin Huang
Angew Chem Int Ed, 2026, 65
DOI: 10.1002/anie.202517452

Discovery of an Exceptionally Orally Bioavailable and Potent HPK1 PROTAC with Enhancement of Antitumor Efficacy of Anti-PD-L1 Therapy
Mingfei Wu, Yiquan Wu, Yuyuan Jin, Xinfei Mao, Shenxin Zeng, Hengyuan Yu, Jingyu Zhang, Yuheng Jin, Yizhe Wu, Tengfei Xu, Yong Chen, Yuwei Wang, Xiaojun Yao, Jinxin Che, Wenhai Huang and Xiaowu Dong
J. Med. Chem., 2024, 67, 13852
DOI: 10.1021/acs.jmedchem.4c00644

A Keap1-recruiting BRD4 degrader offers a single-molecular polypharmacology approach for the treatment of metabolic dysfunction-associated steatohepatitis
Xian Zhang, Yuxin Ge, Mengjie Ye, Xiaolu Wang, Yuanyuan Tong, Chihong Liu, Shicheng Xu, Ziquan Zhao, Qidong You, Xiaoke Guo and Zhengyu Jiang
Free Radical Biology and Medicine, 2025, 232, 15
DOI: 10.1016/j.freeradbiomed.2025.02.042

A Medicinal Chemistry Perspective on Lactate Dehydrogenase: Current Status and Future Directions
Wanyi Pan, Chengpeng Tao, Yi Wu and Feng Jiang
J. Med. Chem., 2025, 68, 16869
DOI: 10.1021/acs.jmedchem.5c00182

Leveraging aptamers for targeted protein degradation
Zhihao Yang, Qiuxiang Pang, Jun Zhou, Chenghao Xuan and Songbo Xie
Trends in Pharmacological Sciences, 2023, 44, 776
DOI: 10.1016/j.tips.2023.05.008

ASDs of PROTACs: Spray-dried solid dispersions as enabling formulations
Nicole Hofmann, Meike Harms and Karsten Mäder
International Journal of Pharmaceutics, 2024, 650, 123725
DOI: 10.1016/j.ijpharm.2023.123725

Tear exosome‐based PROteolysis TArgeting Chimeras nanomedicine for human immunodeficiency virus‐mediated cancer treatment
Nobendu Mukerjee
Clinical and Translational Dis, 2024, 4
DOI: 10.1002/ctd2.326

IgE-FcεRI protein–protein interaction as a therapeutic target against allergic asthma: An updated review
Yan-Jun Liu, Hui-Ying Wang, Ran Wang, Jing Yu, Jin-Jin Shi, Ru-Yi Chen, Guan-Jun Yang and Jiong Chen
International Journal of Biological Macromolecules, 2025, 284, 138099
DOI: 10.1016/j.ijbiomac.2024.138099

Hypoxia-sensitive macrocycle inclusion complexes for targeted protein degradation
Jiachan Lin, Wenyan Wang, An-Kang Ying, Zirui Chen, Dan Zhang, Chendi Ding, Xiaowei Zeng, Dong-Sheng Guo and Hongzhong Chen
Journal of Controlled Release, 2025, 384, 113921
DOI: 10.1016/j.jconrel.2025.113921

Emerging methods to improve PROTAC transport across cell membrane
Fatemeh Veisi and Farangis Ataei
Chemical Engineering Journal, 2026, 530, 173175
DOI: 10.1016/j.cej.2026.173175

Ionizable Nano‐PROTAC Overcomes Endosomal Entrapment for Enhanced LRG1 Degradation and Tumor Suppression
Huan Min, Ming Chao Sun, Kaijing Hu, Yana Zhang, Junyao Li, Yongzheng Li, Lin Du, Wei Ding, Yinlong Zhang, Guangjun Nie and Yingqiu Qi
Angew Chem Int Ed, 2026, 65
DOI: 10.1002/anie.202520235

Advances in DNA-based proteolysis-targeting chimeras technology: Novel strategies for targeting previously undruggable proteins in cancer therapy
Min Hou, Mingda Li, Yulin Li, Xiaobo Wu, Die Long, Di Sun and Jincheng Zeng
Bioorganic & Medicinal Chemistry, 2025, 129, 118297
DOI: 10.1016/j.bmc.2025.118297

Recent advances of small-molecule Mcl-1 inhibitors or degraders as promising anti-cancer agents (2018-present)
Hongjuan Chen, Zixue Yan, Changqing Xiao, Zilong Tang and Yichao Wan
European Journal of Medicinal Chemistry, 2025, 299, 118079
DOI: 10.1016/j.ejmech.2025.118079

Unraveling the secrets of novel PROTACs to improve degradation efficacy
Juan Huang, Xiaoyan Yang, Qiuqian Huang, Yangyang Gao, Pradeepa C. G. Bandaranayake, Wishwajith Kandegama, Charles R. Ashby, Yawen Dong, Zhenchao Wang and Ge-Fei Hao
Mol Divers, 2025
DOI: 10.1007/s11030-025-11273-9

Targeted degradation of hexokinase 2 by a novel engineered bispecific chimeric liposome-based Nano-PROTACs for enhancing tumor chemotherapy
Linlin Gong, Shasha Li, Jiahui Sun, Runjie Liu, Jianling Wang, Simeng Wang, Yuelei Zhao, Li Yan, Meiju Ji, Dan Yang, Peng Hou and Dechun Liu
Biomaterials, 2026, 326, 123651
DOI: 10.1016/j.biomaterials.2025.123651

Targeted degradation of c-Myc through the midnolin–proteasome pathway
Jingyuan Zhao, Huanhuan Wu, Han Yu, Chenyu Li, Yuling Mao, Hong Yuan and Shuai Li
Proc. Natl. Acad. Sci. U.S.A., 2026, 123
DOI: 10.1073/pnas.2520128123

Artificial-intelligence-driven rational design of nanoparticle-mediated targeted protein degradation
Runhan Liu, Yang Liu, Xue Xia, Wei Deng, David Gallego Ortega and Bingyang Shi
Cell Biomaterials, 2026, 100443
DOI: 10.1016/j.celbio.2026.100443

Opportunities and challenges of PROTAC in the treatment of protein-driven diseases
Zhe Zhou, Peng Liu, Yang Li, Xuelian Liu and Jinyao Li
Results in Chemistry, 2026, 24, 103234
DOI: 10.1016/j.rechem.2026.103234

PROTAC-powered synergistic tumor therapy
Xiaoyu Wang, Jingwen Zou, Yixuan Tao, Zhiwen Zhou, Changyu Bian, Zhiqiang Mao and Zhihong Liu
TrAC Trends in Analytical Chemistry, 2026, 196, 118678
DOI: 10.1016/j.trac.2026.118678

Liposomal STAT3-Degrading PROTAC Prodrugs Promote Anti-Hepatocellular Carcinoma Immunity via Chemically Reprogramming Cancer Stem Cells
Xuan Wang, Youbo Zhao, Xin Li, Qiqi Zhang, Jinming He, Yingqi Liu, Menghuan Li and Zhong Luo
Nano Lett., 2024
DOI: 10.1021/acs.nanolett.4c00201

The Ubiquitin–Proteasome System in Tumor Metabolism
Jie Wang, Yuandi Xiang, Mengqi Fan, Shizhen Fang and Qingquan Hua
Cancers, 2023, 15, 2385
DOI: 10.3390/cancers15082385

Recent advances in the molecular design and applications of proteolysis targeting chimera-based multi-specific antiviral modality
Yang Zhou, Shujing Xu, Nerea López-Carrobles, Dang Ding, Xinyong Liu, Luis Menéndez-Arias and Peng Zhan
Acta Materia Medica, 2023, 2
DOI: 10.15212/AMM-2023-0019

Parameterization of Physiologically Based Biopharmaceutics Models: Workshop Summary Report
Xavier Pepin, Sumit Arora, Luiza Borges, Mario Cano-Vega, Tessa Carducci, Parnali Chatterjee, Grace Chen, Rodrigo Cristofoletti, André Dallmann, Poonam Delvadia, Jennifer Dressman, Nikoletta Fotaki, Elizabeth Gray, Tycho Heimbach, Øyvind Holte, Shinichi Kijima, Evangelos Kotzagiorgis, Hans Lennernäs, Anders Lindahl, Raimar Loebenberg, Claire Mackie, Maria Malamatari, Mark McAllister, Amitava Mitra, Rebecca Moody, Deanna Mudie, Flora Musuamba Tshinanu, James E. Polli, Bhagwant Rege, Xiaojun Ren, Gregory Rullo, Megerle Scherholz, Ivy Song, Cordula Stillhart, Sandra Suarez-Sharp, Christer Tannergren, Eleftheria Tsakalozou, Shereeni Veerasingham, Christian Wagner and Paul Seo
Mol. Pharmaceutics, 2024, 21, 3697
DOI: 10.1021/acs.molpharmaceut.4c00526

ClickRNA-PROTAC for Tumor-Selective Protein Degradation and Targeted Cancer Therapy
Xucong Teng, Xuan Zhao, Yicong Dai, Xiangdong Zhang, Qiushuang Zhang, Yuncong Wu, Difei Hu and Jinghong Li
J. Am. Chem. Soc., 2024, 146, 27382
DOI: 10.1021/jacs.4c06402

Molecular Mechanisms and Therapeutic Potential of Degron-Mediated Proteostasis Regulation in Neurodegenerative Diseases
D. S. Nishanth, Urvi Sinha, Tanishque Verma, Bharathi Kalidass, Saravana Prakash Thirumuruganandham and Gothandam Kodiveri Muthukaliannan
Cell Mol Neurobiol, 2026, 46
DOI: 10.1007/s10571-025-01659-6

Nano-formulations in disease therapy: designs, advances, challenges, and future directions
YunYan Shi, Xiao Li, Zhiyuan Li, Jialin Sun, Tong Gao, Gang Wei and Qie Guo
J Nanobiotechnol, 2025, 23
DOI: 10.1186/s12951-025-03442-7

Organoids in skin wound healing
Zitong Wang, Feng Zhao, Hongxin Lang, Haiyue Ren, Qiqi Zhang, Xing Huang, Cai He, Chengcheng Xu, Chiyu Tan, Jiajie Ma, Shu Duan and Zhe Wang
Burns & Trauma, 2025, 13
DOI: 10.1093/burnst/tkae077

Revolutionizing Medicine: The Promise of Camouflage Nanoparticles - A Review
Vajagathali Mohammed and Nikitha Shalom Richard
CNM, 2025, 10, 22
DOI: 10.2174/0124054615273067231011110436

Recent advances in developing targeted protein degraders
Binbin Cheng, Hongqiao Li, Xiaopeng Peng, Jianjun Chen, Chuxiao Shao and Zhihua Kong
European Journal of Medicinal Chemistry, 2025, 284, 117212
DOI: 10.1016/j.ejmech.2024.117212

Potential of the nanoplatform and PROTAC interface to achieve targeted protein degradation through the Ubiquitin–Proteasome system
Hanshu Xie and Chao Zhang
European Journal of Medicinal Chemistry, 2024, 267, 116168
DOI: 10.1016/j.ejmech.2024.116168

Immunoconjugates as an Efficient Platform for Drug Delivery: A Resurgence of Natural Products in Targeted Antitumor Therapy
Rositsa Mihaylova, Denitsa Momekova, Viktoria Elincheva and Georgi Momekov
Pharmaceuticals, 2024, 17, 1701
DOI: 10.3390/ph17121701

Dual-drug codelivery gelatin-based hydrogel of ARV-471 and Palbociclib enhances synergistic effect in breast cancer treatment
Irene Sevilla-Carrillo, María del Mar Noblejas-López, José Antonio Vázquez, Alberto Ocaña, Iván Bravo and Carlos Alonso-Moreno
Sci Rep, 2025, 16
DOI: 10.1038/s41598-025-30803-x

Remodeling the Physicochemical and Pharmacokinetic Properties of PROTAC via Lipid Nanodisks for Cancer Therapy
Meichen Pan, Chunrong Yang, Zhongliang Fu, Yuchen Yang, Ying Zhuo, Hongwei Hou and Jinghong Li
Advanced Science, 2025, 12
DOI: 10.1002/advs.202501384

Rational modification of PROTACs for tumor-selective protein degradation
Zhongliang Fu, Meichen Pan, Chunrong Yang, Hongwei Hou and Jinghong Li
Advanced Drug Delivery Reviews, 2026, 230, 115775
DOI: 10.1016/j.addr.2026.115775

Current advances and development strategies of orally bioavailable PROTACs
Shenxin Zeng, Yingqiao Ye, Heye Xia, Jingli Min, Jiamei Xu, Zunyuan Wang, Youlu Pan, Xinglu Zhou and Wenhai Huang
European Journal of Medicinal Chemistry, 2023, 261, 115793
DOI: 10.1016/j.ejmech.2023.115793

Split‐Deliver‐Click: Tumor‐Specific Protein Degradation via “AND” Logic‐Gated In‐Cell Bioorthogonal Clicking of PROTACs
He Dong, Cilong Chu, Ihsan Ullah, Qing Xu, Zhenhai Pan and Youyong Yuan
Angew Chem Int Ed, 2026, 65
DOI: 10.1002/anie.202520774

Rational design of lipid-based nanoparticles for targeted anticancer therapies
María Arenas-Moreira, Alberto Ocaña, Carlos Alonso-Moreno and Iván Bravo
Drug Deliv. and Transl. Res., 2026
DOI: 10.1007/s13346-026-02110-z

Solubility Enhanced Formulation Approaches to Overcome Oral Delivery Obstacles of PROTACs
Florian Pöstges, Kevin Kayser, Jan Appelhaus, Marius Monschke, Michael Gütschow, Christian Steinebach and Karl G. Wagner
Pharmaceutics, 2023, 15, 156
DOI: 10.3390/pharmaceutics15010156